NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes and animals. Our technology targets two special cellular components known as organelles that harbor their own DNA. Those organelles are called mitochondria and chloroplasts. Both organelles are important to create energy for cells to grow. They are also critical for producing various biochemical molecules key to specific pathways and functions. Our genome technology has broad application areas. They range from industrial biotechnology to animal and human healthcare as well as to agriculture. Our mission is to harness the potentials of organelles to make our society a better place to live.
Location: United States, Delaware, Wilmington
Employees: 1-10
Total raised: $7.85M
Founded date: 2016
Investors 5
| Date | Name | Website |
| - | THRIVE Agr... | thriveagri... |
| - | MarsBio | marsbio.vc |
| - | The Innova... | innovation... |
| - | Breakout L... | breakoutla... |
| - | Grantham F... | granthamfo... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.07.2022 | Seed | $7.85M | - |
Mentions in press and media 5
| Date | Title | Description |
| 14.07.2025 | Pretzel Therapeutics: Investment Raised From The Mito Fund | The United Mitochondrial Disease Foundation’s venture philanthropy arm, The Mito Fund, has invested in Pretzel Therapeutics, a Massachusetts-based company with research facilities in Mölndal, Sweden. Pretzel is focused on using cellular ene... |
| 11.07.2025 | The Mito Fund Announces Investment in Pretzel Therapeutics | The United Mitochondrial Disease Foundation's venture philanthropy arm has invested in Pretzel Therapeutics, a company working on novel treatments for POLG and mtDNA depletion related mitochondrial diseases. PITTSBURGH, July 11, 2025 /PRNew... |
| 12.07.2022 | NAPIGEN Completes $7.85 Million Funding Round to Advance Its Mitochondrial and Chloroplast Gene Editing Technology | WILMINGTON, Del., July 12, 2022 (GLOBE NEWSWIRE) -- NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, completed a $7.85 million seed funding round. The Grantham Foundation and RA Capital Man... |
| 12.07.2022 | NAPIGEN Completes $7.85M Seed Financing | WILMINGTON, DE, NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, completed a $7.85 million seed funding round. >> Click here for more funding data on NAPIGEN >> To export NA... |
| 26.01.2021 | RealLIST Startups: These are the young Delaware companies to watch in 2021 | Five years of Delaware startups. When Technical.ly published the inaugural RealLIST Startups in 2017, 10 ten young and exciting local companies we listed included companies that are still going strong: DeliveryCircle (our first #1 RealLIST ... |